Zhu Yi (#258)
- $ 12 B
- Pharmaceuticals
- China
- M
- 62 Years
'A form of double taxation': Are management fees on new houses quietly getting out of control?
Trump Official Blames Biden Admin for Economic ‘Mess’ — As Resurfaced Clip Shows Him Saying Trump Would Own the Economy By 2026
Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?
Is Transocean Ltd. (RIG) A Good Stock To Buy Now?
Tesla is selling Chinese-made cars in Canada to escape the tariffs that both China and America imposed on it
Insecurity didn’t start with Tinubu, group defends president’s security record
Vibrating pillow sleeve warns deaf sleepers of burglars and fires
How Kepler built verifiable AI for financial services with Claude
Is ASML Holding N.V. (ASML) A Good Stock To Buy Now?
5-Letter Words Ending in ‘Y’ to Help You Improve Your Wordle Skills
About Me
Zhu Yi is the chairman of Biokin Pharmaceutical, a developer of drugs including anesthesia injections, cancer drugs as well as traditional Chinese medicine treatments. The company went public in Shanghai in 2023, raising $136 million; it has been seeking a Hong Kong IPO since 2024. Biokin's U.S. subsidiary SystImmune signed in 2023 an $8.4 billion deal with Bristol Myers Squibb to jointly develop and commercialize a potential cancer treatment worldwide. Zhu taught immunology and microbiology at West China University of Medical Sciences before striking out on his own.
Achievements
Career Highlights
A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Zhu Yi’s rise and global influence.
Wealth Growth
Net Worth Growth Over Time
Tracking Zhu Yi’s net worth journey over the years, highlighting key growth phases and financial milestones.
Current Net Worth: $12.0B
(May 4, 2026)
© Iconic Billionaires